Effect of Anti-CD14 Antibody on Experimental Periodontitis Induced by Porphyromonas gingivalis Lipopolysaccharide

The Japanese Journal of Pharmacology

Yusuke Kowashi³  Mitsuko Shinohara¹  Yasutaka Azuma¹  Kiyoshi Ohura¹  Junzo Tanaka²  Masanori Kikuchi²  Pao-Li Wang¹  Yasushi Suetsugu²  Takeo Fujii³  Mari Oido-Mori³ 

[1] Department of Pharmacology, Osaka Dental University;National Institute for Materials Science, Advanced Materials Laboratory, Bioceramics Research Group;Department of Periodontology and Endodontology, School of Dentistry, Health Sciences University of Hokkaido

关键词: Lipopolysaccharide;    CD14;    Periodontal disease;    Experimental periodontitis;    Animal model;   

DOI  :  10.1254/jjp.89.176

学科分类：药理学

来源: Nihon Yakuri Gakkai Henshuubu / Japanese Pharmacological Society

【 摘 要 】

References(32)Cited-By(8)The lipopolysaccharide (LPS) released by Porphyromonas gingivalis, a Gram-negative bacterium found in the periodontal pockets of patients with periodontitis, induces bone resorbing activity in vivo. We previously showed that a receptor for LPS on human gingival fibroblasts and gingival epithelial cells is CD14. In this study, we established a mouse model of experimental periodontitis by applying a P. gingivalis LPS solution to the buccal region of mice. P. gingivalis LPS-induced bone resorption and interleukin-6 production in the gingival tissues were significantly inhibited by pretreatment with anti-CD14 antibody for 5 weeks prior to LPS treatment. This result suggests that anti-CD14 antibody may be usable as a prototype for the development of drugs for the treatment of periodontal disease.

【 授权许可】

Unknown